格隆汇2月2日丨艾德生物(300685.SZ)公布，截止2026年1月31日，公司通过回购专用证券账户以集中竞 价交易方式实施回购股份696,400股，占公司目前总股本的0.18%，回购股份的最高成交价为22.16元/ 股，最低成交价为20.50元/股，支付的总金额为14,990,827.10元（不含交易费用）。本次回购符合公司 既定的回购股份方案及相关法律法规的要求。 ...

证券之星消息，2月2日生物制品板块较上一交易日下跌2.83%，神州细胞领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。生物制品板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日生物制品板块主力资金净流出6.42亿元，游资资金净流入3.89亿元，散户资金净 流入2.52亿元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 301207 | 华兰疫苗 | 1967.06万 | 5.06% | -124.16万 | -0.32% | -1842.90万 | -4.74% | | 002880 卫光生物 | | 1473.64万 | 8.15% | 246.89万 | 1.37% | -1720.53万 | -9.52 ...

Core Viewpoint - Shanghai Yizhong (688091.SH) reported a significant increase in both revenue and net profit for the year 2025, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance directory [1] Financial Performance - The company achieved an operating revenue of 317 million yuan in 2025, representing a year-on-year growth of 82.72% [1] - The net profit attributable to the parent company reached 64.132 million yuan, marking a substantial year-on-year increase of 819.42% [1] Product Impact - The inclusion of paclitaxel polymer micelles in the national medical insurance directory significantly enhanced market access and the number of patients using the product, contributing to the overall revenue and profit growth for the company in 2025 [1]

Group 1 - The core point of the article is that Shanghai Yizhong reported significant growth in its financial performance for the year 2025, with total operating revenue reaching 317 million yuan, an increase of 82.72% year-on-year [1] - The net profit attributable to shareholders of the listed company was 64.132 million yuan, reflecting a remarkable year-on-year growth of 819.42% [1] - The basic earnings per share for the company stood at 0.31 yuan [1]

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **pharmaceutical industry**, particularly the **CDMO (Contract Development and Manufacturing Organization)** sector, highlighting key players like **Lonza** and **Samsung Biologics** [1][2]. Core Insights and Arguments - **Lonza's Financial Performance**: - For the year 2025, Lonza reported sales of **65.31 billion Swiss Francs**, with a constant exchange rate (CER) year-over-year growth of **21.7%**. - The core EBITDA margin improved by **1.4 percentage points** to **31.6%**, exceeding the revised annual expectations [1]. - The company maintains an optimistic outlook for 2026, projecting a **11-12%** CER year-over-year growth in CDMO sales and an EBITDA margin surpassing **32%** [1]. - **Upcoming Financial Disclosures**: - February will see a concentrated disclosure period for several leading CXO companies, which will provide insights into revenue, profits, orders, and capacity planning, along with 2026 operational guidance [2]. - **Strategic Collaborations**: - On January 30, **Shijiazhuang Pharmaceutical Group** announced a strategic R&D collaboration with **AstraZeneca** to develop innovative long-acting peptide drugs using its proprietary sustained-release drug delivery technology and AI drug discovery platform [2]. - **Growth Projections for CXO Companies**: - Given the order-to-performance conversion cycle, it is anticipated that CXO companies will continue to experience rapid growth over the next **1-2 years** [2]. Additional Important Content - **Medical Devices and Biologics**: - Roche reported positive topline results from the **CT388-103 Phase II clinical trial**, suggesting continued monitoring of subsequent R&D progress [3]. - **Medical Services and Consumer Healthcare**: - **Gushengtang** plans to issue convertible bonds totaling **$110 million** (approximately **860 million Hong Kong Dollars**) [3]. - **Synergistic Opportunities**: - There is potential for deep collaboration in business synergy and resource integration, which could yield significant synergistic effects [4]. - **Chinese Herbal Medicine**: - Some companies are expected to achieve good results in inventory reduction, and with a low base, the operational trend for 2026 is anticipated to improve, suggesting potential turnaround opportunities for certain companies [4]. - **Overall Industry Recovery**: - The combination of overseas CXO annual reports and 2026 performance guidance, along with domestic CXO companies' 2025 performance forecasts, indicates a clear recovery rhythm and upward trend in the industry, presenting strong investment value and suggesting active positioning [4].

Core Viewpoint - Sangfor Biopharma (三生国健) is expected to achieve significant revenue and profit growth in 2025, driven by a collaboration with Pfizer and the recognition of substantial income from a project authorization fee. Group 1: Stock Performance - As of January 30, 2026, Sangfor Biopharma's stock closed at 60.22 CNY, up 2.48% from the previous week [1] - The stock reached a weekly high of 66.28 CNY on January 27 and a low of 56.88 CNY on January 26 [1] - The company's current total market capitalization is 37.221 billion CNY, ranking 7th out of 51 in the biopharmaceutical sector and 562nd out of 5184 in the A-share market [1] Group 2: Earnings Forecast - Sangfor Biopharma forecasts a total revenue of approximately 4.2 billion CNY for the year 2025 [4] - The company anticipates a net profit attributable to shareholders of around 2.9 billion CNY for 2025 [3] - The expected net profit after deducting non-recurring gains and losses is projected to be about 2.8 billion CNY, reflecting a year-on-year growth of approximately 1,038.21% [5][7] Group 3: Revenue Drivers - The significant growth in earnings is primarily attributed to the collaboration with Pfizer, which includes a project authorization fee that will contribute approximately 2.89 billion CNY to revenue [5][7] - The projected revenue growth represents an increase of about 251.76% compared to the previous year [5]

Core Viewpoint - The company Zhixiang Jintai (688443) is experiencing significant financial challenges, with projected losses for 2025 and a focus on product development in the autoimmune disease sector. Financial Performance - As of January 30, 2026, Zhixiang Jintai's stock closed at 28.29 yuan, down 3.25% from the previous week [1] - The company expects a net profit loss of 524 million to 630 million yuan for the year 2025 [1] - Projected operating revenue for 2025 is between 209 million and 251 million yuan [1] - The expected net profit loss attributable to shareholders is between 481 million and 587 million yuan [1] - The total market capitalization is 10.373 billion yuan, ranking 28th out of 51 in the bioproducts sector and 1969th out of 5184 in the A-share market [1] Product Development and Clinical Trials - The GR1802 injection (Tairiqibai monoclonal antibody) for moderate to severe atopic dermatitis has had its new drug application accepted as of September 2025 and is currently under review [2] - Other indications for GR1802, including chronic sinusitis with nasal polyps and chronic spontaneous urticaria, are in Phase III clinical trials, while asthma is in Phase II [2] - The GR1803 injection for multiple myeloma has received conditional approval for listing and is on the priority review list [7] Strategic Partnerships and Market Positioning - The company is strategically focusing on the autoimmune disease sector, particularly with the commercialization of its products [2] - The inclusion of the product Sairiqi monoclonal antibody in the national medical insurance directory is expected to enhance hospital access and reduce patient costs, thereby improving treatment adherence [2] - The company has established a professional business development team to explore potential partnerships and collaborations [3] Revenue Growth and Cost Management - The sales revenue from the product Jinlixi is expected to drive a nearly sixfold increase in revenue for 2025 [5] - Research and development expenses are projected to be between 425 million and 519 million yuan, reflecting a year-on-year decrease of 14.77% to 30.27% [8] - The anticipated net profit loss is expected to decrease by 26.32% to 39.71% compared to the previous year, primarily due to increased sales and the absence of share-based payment expenses in 2025 [8]

Core Viewpoint - The company, JIANGSU JINDIKE BIOLOGICAL TECHNOLOGY CO., LTD, is forecasting a significant loss for the fiscal year 2025, with net profit expected to be between -180 million to -160 million yuan, indicating an increase in losses compared to the previous year [2] Financial Performance Forecast - The company anticipates a net profit attributable to the parent company for 2025 to be between -180 million to -160 million yuan, representing an increase in losses of 66.5 million to 86.5 million yuan compared to the previous year, which is a year-on-year increase in losses of 71.12% to 92.51% [2] - The expected net profit after deducting non-recurring gains and losses is projected to be between -185 million to -165 million yuan, with an increase in losses of 58.8 million to 78.8 million yuan compared to the previous year, reflecting a year-on-year increase in losses of 55.33% to 74.16% [2] Previous Year Performance - In 2024, the company reported a total profit of -115.75 million yuan, with a net profit attributable to the parent company of -93.50 million yuan, and a net profit after deducting non-recurring gains and losses of -106.22 million yuan, resulting in a basic and diluted earnings per share of -0.76 yuan [4] Reasons for Performance Changes - The company has increased production efficiency and improved labor discipline, leading to a sales revenue of approximately 112 million yuan for 2025, which shows a certain degree of growth compared to the previous year. However, the company remains in a loss position due to increased R&D investments related to the four-valent influenza vaccine project and the three-valent influenza vaccine project [5] - The company decided not to sell certain in-process and finished products due to equipment failures and material batch differences, leading to a provision for asset impairment and inventory write-offs totaling approximately 41.99 million yuan [6] Asset Impairment and Inventory Write-off - The company has conducted a comprehensive review and assessment of its assets as of December 31, 2025, and has decided to recognize an asset impairment provision and write off certain inventories totaling approximately 41.99 million yuan, which will reduce the total profit for 2025 by the same amount [10][11] - The seasonal nature of the production and sales of the four-valent influenza vaccine has been noted, with production primarily occurring in the second and third quarters and sales in the third and fourth quarters of the year [11]

Core Viewpoint - The company has approved a guarantee plan for the year 2025, which includes significant amounts allocated to subsidiaries for business development needs [1][11]. Group 1: Guarantee Amounts and Adjustments - The company plans to provide a guarantee of 710 million yuan to Heilongjiang Yipin Trading Co., Ltd. and 1.1 billion yuan to Inner Mongolia Yipin Biotechnology Co., Ltd. for the year 2025 [1]. - A total of 160 million yuan in guarantee capacity from Ningxia Yipin Trading Co., Ltd. will be reallocated to Heilongjiang Yipin Trading Co., Ltd. due to its asset-liability ratio exceeding 70% [1]. Group 2: Actual Guarantee Situation - In the fourth quarter of 2025, the company signed new guarantee contracts amounting to 330 million yuan, with an actual usage of 220 million yuan [1]. Group 3: Guarantee Recipients and Their Status - Heilongjiang Yipin Trading Co., Ltd. and Inner Mongolia Yipin Biotechnology Co., Ltd. are the main recipients of the guarantees, both of which are controlled subsidiaries of the company [3][11]. - As of the announcement date, the guarantee recipients are not listed as dishonest executors [4]. Group 4: Guarantee Agreement Details - The company has entered into guarantee agreements with various banks, including a 50 million yuan guarantee with Agricultural Bank of China and an 80 million yuan guarantee with Huaxia Bank [4][7]. - The guarantees cover a range of obligations including principal, interest, penalties, and other costs associated with debt recovery [6][10]. Group 5: Necessity and Reasonableness of Guarantees - The planned guarantees are deemed necessary for meeting the operational funding needs of the company and its subsidiaries, aligning with the company's overall business development strategy [11]. - The board of directors believes that the guarantees will not adversely affect the company's normal operations or financial condition [11]. Group 6: Cumulative Guarantee Situation - As of December 31, 2025, the total external guarantee balance is 2.940767 billion yuan, accounting for 37.34% of the company's latest audited net assets attributable to shareholders [11]. - There are no overdue guarantees or litigation related to guarantees outside the consolidated financial statements [11].

智通财经APP讯， 安旭生物(688075.SH)发布2025 年年度业绩预告，预计2025年年度实现归属于母公司 所有者的净利润7100万元到8500万元，与上年同期(法定披露数据)相比，将减少10,729.53 万元到 12,129.53万元，同比减少55.80%到63.08%。 报告期内，公司主营业务保持稳健发展，为巩固在产业领域内的长期竞争优势，公司保持原有几大技术 平台的先进性之外，持续加大对新技术平台的战略性投入，同时国内外市场及注册证书等拓展，海外分 子公司的布局致使费用增加。 ...